CNTNAP4: A Potential Drug Target and Biomarker for Contactin-Associated Protein-Like 4 Precursor

Target Name: CNTNAP4

NCBI ID: G85445

CNTNAP4

CNTNAP4: A Potential Drug Target and Biomarker for Contactin-Associated Protein-Like 4 Precursor

Contactin-associated protein-like 4 (CNTNAP4) is a protein that has been identified as a potential drug target and biomarker for various diseases, including neurodegenerative disorders, pain, and inflammation. CNTNAP4 is a key regulator of the neural plasticity and development, and its dysfunction has been implicated in a number of neurological and psychiatric disorders. The present article will provide an overview of CNTNAP4, its functions, and potential as a drug target and biomarker.

Function and Localization

CNTNAP4 is a 21-kDa protein that is expressed in a variety of tissues, including brain, spinal cord, and peripheral tissues. It is primarily localized to the cytoplasm and has been shown to be involved in the regulation of neural stem/progenitor cell (NSPC) proliferation, differentiation, and plasticity. CNTNAP4 has been shown to play a role in the regulation of neuronal excitability and synaptic plasticity, and its dysfunction has been implicated in a number of neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia.

Potential Drug Target

CNTNAP4 has been identified as a potential drug target due to its involvement in the regulation of neuronal excitability and synaptic plasticity. Several studies have shown that CNTNAP4 inhibitors can enhance neurotransmitter release and improve neuronal excitability, which may have therapeutic potential for the treatment of neurological and psychiatric disorders. Additionally, CNTNAP4 has been shown to play a role in the regulation of pain perception and neuroinflammation, and its dysfunction has been implicated in the development of chronic pain. Therefore, CNTNAP4 may be a promising target for the development of pain and neurodegenerative disorder therapies.

Biomarker

CNTNAP4 has also been identified as a potential biomarker for several neurological and psychiatric disorders. Several studies have shown that CNTNAP4 levels are altered in a variety of neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. Additionally, CNTNAP4 has been shown to be involved in the regulation of neurotransmitter release and neuronal excitability, which may be useful as biomarkers for these disorders. Therefore, CNTNAP4 may be a promising biomarker for the diagnosis and treatment of neurological and psychiatric disorders.

Conclusion

In conclusion, CNTNAP4 is a protein that has been identified as a potential drug target and biomarker for several neurological and psychiatric disorders. Its functions in the regulation of neural stem/progenitor cell proliferation, differentiation, and plasticity, as well as its involvement in the regulation of neuronal excitability and synaptic plasticity, make it a promising target for the development of therapies for these disorders. Additionally, CNTNAP4 has been shown to be involved in the regulation of pain perception and neuroinflammation, which may make it a useful biomarker for the diagnosis and treatment of these disorders. Further research is needed to fully understand the functions of CNTNAP4 and its potential as a drug target and biomarker.

Protein Name: Contactin Associated Protein Family Member 4

Functions: Presynaptic protein involved in both dopaminergic synaptic transmission and GABAergic system, thereby participating in the structural maturation of inhibitory interneuron synapses. Involved in the dopaminergic synaptic transmission by attenuating dopamine release through a presynaptic mechanism. Also participates in the GABAergic system (By similarity)

The "CNTNAP4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CNTNAP4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets